Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- L-dopa Induced DyskinesiaParkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT00888004
- Locations
- 🇩🇪
Novartis Investigative Site, Tubingen, Germany
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
Phase 2
Completed
- Conditions
- SeizuresEpilepsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 37
- Registration Number
- NCT00887861
- Locations
- 🇩🇪
Novartis Investigator Site, Munich, Germany
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Candesartan+HCTZ - Phase 1Drug: Aliskiren+HCTZ - Phase 2Drug: Aliskiren+HCTZ+amlodipine - Phase 3
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 186
- Registration Number
- NCT00867490
- Locations
- 🇩🇪
Investigative Site, Chemnitz, Germany
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 822
- Registration Number
- NCT00865020
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
🇭🇺Invesitagtive Site, Budapest, Hungary
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 33
- Registration Number
- NCT00856193
- Locations
- 🇩🇪
Harrison Clinical Research Deutschland GmbH, Albrechtstrasse 14, Munich, Germany
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 443
- Registration Number
- NCT00853957
- Locations
- 🇺🇸
Investigative Site, Milwaukeee, Wisconsin, United States
A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Adjuvanted and un-adjuvanted influenza vaccines
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 410
- Registration Number
- NCT00848887
- Locations
- 🇧🇪
UCL St. Luc - Pharmacy, Brussel, Belgium
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
Phase 3
Completed
- Conditions
- Moderate to Severe Hypertension
- Interventions
- Drug: Aliskiren/amlodipine 300/10 mg tablet
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 485
- Registration Number
- NCT00841672
- Locations
- 🇪🇸
Investigative Site, Madrid, Spain
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Phase 3
Completed
- Conditions
- Pandemic Influenza Disease
- Interventions
- Biological: Trivalent influenza virus vaccine (TIV)Biological: Placebo (PL)Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1)Biological: Adjuvanted trivalent influenza virus vaccine (aTIV)
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3647
- Registration Number
- NCT00841763
- Locations
- 🇩🇪
12 Sites, München, Germany
🇫🇮Tampere Vaccine Research Clinic (15 sites), Tampere, Finland
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00834041
- Locations
- 🇵🇱
Investigative Site, Warsaw, Poland
© Copyright 2025. All Rights Reserved by MedPath